Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Financing Activities: 2015-2024

Historic Cash from Financing Activities for Corvus Pharmaceuticals (CRVS) over the last 9 years, with Dec 2024 value amounting to $49.0 million.

  • Corvus Pharmaceuticals' Cash from Financing Activities rose 620.00% to $360,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $55.0 million, marking a year-over-year increase of 595.98%. This contributed to the annual value of $49.0 million for FY2024, which is 524.16% up from last year.
  • As of FY2024, Corvus Pharmaceuticals' Cash from Financing Activities stood at $49.0 million, which was up 524.16% from $7.9 million recorded in FY2023.
  • In the past 5 years, Corvus Pharmaceuticals' Cash from Financing Activities registered a high of $62.2 million during FY2021, and its lowest value of $1.3 million during FY2020.
  • Its 2-year average for Cash from Financing Activities is $28.4 million, with a median of $28.4 million in 2023.
  • Data for Corvus Pharmaceuticals' Cash from Financing Activities shows a peak YoY skyrocketed of 5,358.33% (in 2020) over the last 5 years.
  • Corvus Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $1.3 million in 2020, then spiked by 4,644.89% to $62.2 million in 2021, then reached $7.9 million in 2023, then spiked by 524.16% to $49.0 million in 2024.